摘要
目的：探讨喹硫平治疗双相情感障碍抑郁发作的临床疗效和安全性。方法将66例双相情感障碍抑郁发作患者随机分为两组，研究组口服喹硫平治疗，对照组口服喹硫平联合碳酸锂治疗，观察8周。治疗前后采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果对照组治疗第1周、2周、4周末汉密顿抑郁量表评分较研究组下降更显著（ P＜0．05或0．01）；治疗8周末，研究组显效率75．0％、总有效率93．8％，对照组为76．7％、96．7％，两组疗效比较差异无显著性（P＞0．05）。研究组总体不良反应发生率显著低于对照组（P＜0．05）。结论喹硫平治疗双相情感障碍抑郁发作疗效显著，虽没有喹硫平联合碳酸锂治疗起效快，但总体疗效相当，且安全性更高，依从性更好。
Objective To explore the efficacy and safety of quetiapine in the treatment of depressive phase of bipolar affective disorder .Methods Sixty-six patients with depressive phase of bipolar affective disorder were randomly assigned to research group taking orally quetiapine and control group doing quetiapine plus lithium carbonate for 8 weeks . Clinical efficacies were assessed with the Hamilton Depression Scale （HAMD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before and after treatment .Results At the end of the 1st ,2nd and 4th week the HAMD scores lowered more significantly in control than research group （P〈0 .05 or 0 .01）;at the end of the 8th week obvious and total rate were re-spectively 75 .5% and 93 .8% in research and 76 .7% and 96 .7% in control group ,which showed no signif-icant differences （P〉0 .05） .Total incidence of adverse reactions was significantly lower in research than control group （P〈0 .05） .Conclusion Quetiapine has an evident effect in depressive phase of bipolar af-fective disorder ,it takes effect slower than quetiapine plus lithium carbonate does ,but their total efficacy are equivalent ,the former has higher safety and better compliance .
出处
《临床心身疾病杂志》
CAS
2013年第6期504-506,共3页
Journal of Clinical Psychosomatic Diseases
